Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
23.65
-0.12 (-0.50%)
At close: Mar 18, 2026, 4:00 PM EDT
23.70
+0.05 (0.21%)
After-hours: Mar 18, 2026, 7:37 PM EDT
Syndax Pharmaceuticals Revenue
In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth. Syndax Pharmaceuticals had revenue of $68.73M in the quarter ending December 31, 2025, with 794.90% growth.
Revenue (ttm)
$172.60M
Revenue Growth
+628.88%
P/S Ratio
12.10
Revenue / Employee
$578,362
Employees
298
Market Cap
2.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 460.16M |
| Adaptive Biotechnologies | 276.98M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 55.23M |
| Ascentage Pharma Group International | 54.52M |
SNDX News
- 13 hours ago - Syndax Pharma: Two Drug Launches Fuel Transformational Growth - Seeking Alpha
- 6 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 20 days ago - Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 23 days ago - Syndax Announces Participation in March Investor Conferences - GlobeNewsWire
- 27 days ago - Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - GlobeNewsWire
- 4 weeks ago - Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 - Seeking Alpha